Chile says different vaccine brands are effective against different coronavirus
Date 06 Aug 2021 time 10:29
Actual use in Chile finds different brands of vaccine effective at protecting against Covid-19, Pfizer highest, Sinovac lowest.
Reuters news agency reported that Chile’s Ministry of Health said. Sinovac’s Covid-19 vaccine was 58.8% effective in preventing Covid-19 illness among millions of Chileans vaccinated between Feb-July, while Pfizer’s vaccine was 87.7 effective. % and that of AstraZeneca is 68.7% effective.
The above information is about the effectiveness of different brands of vaccines. Based on the latest actual use published by the official
Chile has started vaccinating its citizens since last month. December last year, which is considered one of the countries that started the fastest injection. And now more than 60% of the population has been vaccinated with full-dose vaccinations using Sinovac as the main vaccine.
Chilean health official Rafael Araos said the Sinovac vaccine was 86 percent effective in preventing hospitalizations, 89.7% effective at preventing intensive care unit admissions and 86 percent preventing wastage. life
A similar study in April found that the Sinovac vaccine was 67 percent effective in preventing illness. It is 85% effective in preventing hospitalizations and 80% in preventing death. which indicates that The effectiveness of preventing severe illnesses from Covid-19 has increased, while the effectiveness of prevention of severe illnesses has decreased.
Araos revealed that The decline in vaccine effectiveness over time is inevitable. This is especially true of the more violent species like the Delta. “If the delta becomes the dominant strain, the vaccine has a weaker response. The efficacy of the vaccine is rapidly deteriorating.” It also called for a 3rd dose injection.
The Chilean government also published data on the efficacy of the vaccine. Pfizer-BioNTech and AstraZeneca, also used in Chile. In the same period, Pfizer’s vaccine was 87.7% effective in preventing illness, 98% at preventing intensive care, and 100% at preventing death.
AstraZeneca’s vaccine prevented 68.7% of illnesses during the same period. Prevents 98% of admission to the ICU and 100% prevents death.
The Chilean research tested the efficacy of the vaccine in populations who received 2 doses of either brand of vaccine, received 1 dose and had not received at all. The Sinovac vaccine was studied in a population of 8.6 million people. Pfizer’s vaccine. -BioNTech studied in a population of 4.5 million and of AstraZeneca in a population of 2.3 million.
Photo by Martin BERNETTI / AFP
<!–
–>
.
